Life sciences span a wide range of disciplines that study living organisms in six categories, from molecules and cells to ecosystems and human health. The category that intersects in our world is Applied Life Sciences. And more specifically these fields that translate biological knowledge into practical solutions.
- Biotechnology – using living systems for technology and innovation
- Pharmacology – drug action and development
- Biomedical Science – disease mechanisms, diagnostics, therapeutics
- Stem Cell Biology & Regenerative Medicine – cell-based therapies
In this monthly report you will find news and highlights in the Applied Life Science.
Biotechnology
T-CURX Acquires Pantherna Therapeutics to Accelerate Clinical Translation of its Non-Viral In Vivo CAR-T Strategies
Leading CAR-T company T-CURX announces the signing of a definitive agreement for the acquisition of Pantherna Therapeutics, a German biotechnology company specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technologies. Pantherna will continue to operate as Pantherna Therapeutics as a wholly owned subsidiary of T-CURX. The complementary expertises and proprietary technologies of both companies will be leveraged to accelerate clinical translation of CAR-T strategies with a clear focus on clinical validation of in vivo CAR-T therapies. T-CURX is a Würzburg-headquartered private biotech company with an additional site in Munich with strong expertise, proprietary technologies and track record for clinical translation of non-viral, transposon-based CAR-T therapies for novel and differentiated targets.
Cercare Medical Receives FDA 510(k) Clearance for Cone-Beam CT Perfusion
Cercare Medical, a provider of advanced neuroimaging software, announced FDA 510(k) clearance (K253831) for its Cone-Beam CT (CBCT) Perfusion solution, enabling qualitative perfusion assessment directly from cone-beam CT data acquired during neurointerventional procedures.
United Immunity Acquires Macrophage Assets from Carisma Therapeutics for the Treatment of Cancer and Liver Fibrosis
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineering of disease-associated macrophages and dendritic cells, announced the acquisition of multiple assets from Carisma Therapeutics Inc. United Immunity plans to leverage these innovative assets in combination with its PEG-free, pullulan-coated lipid nanoparticle (P-LNP) delivery system to generate in vivo CAR-M and other genetically engineered macrophages. This integrated approach aims to advance next-generation therapies for solid tumors and fibrosis diseases.
Pharmacology
Vetter Achieves Platinum Status as a Best Managed Company
Vetter, a Contract Development and Manufacturing Organization (CDMO), has been named a Best Managed Company for the seventh year in a row. The family-owned business was the only company in this year’s competition to be newly awarded Platinum status. The prestigious prize is awarded by Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Bundesverband der Deutschen Industrie e.V. (Federation of German Industries, BDI) to companies for outstanding achievements in leadership and management. The jury evaluates companies according to four value drivers: strategy, productivity, culture and commitment, and governance and finance. In 2026, the CDMO received the award primarily for consistent further development of its corporate strategy and its operational processes in the context of a globally challenging environment. The trophy and certificate were presented to Vetter at an awards ceremony on May 21 at the Gesellschaftshaus Palmengarten in Frankfurt, Germany.
Stem Cell Biology & Regenerative Medicine
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Gilead Sciences and Lakefront Biotherapeutics NV announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio and will be the foundation of Lakefront’s clinical development pipeline. Gamgertamig is designed to enable rapid and deep plasma cell and B cell depletion following a limited subcutaneously administered treatment course with the potential to induce durable disease control in severe antibody-mediated orphan diseases including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies as early as 2027.
ProBioGen Launches AGE1.CR.ReX Designer Cell Line for High-Titer Poxvirus Production
ProBioGen announced the launch of AGE1.CR.ReX®, its next-generation avian designer cell line for stable, high-titer poxvirus production and rapid generation of recombinant modified vaccinia Ankara (MVA). Enabled for switchable gene expression and the proprietary TetherexX™ System, the new platform is designed to accelerate and simplify the development of modern poxvirus-based vaccines and oncolytic viruses while improving genetic stability and manufacturing reliability.
MedTech and Medical Devices
i-GENTIC AI Expands GENIE to Enforce Full FDA Compliance Lifecycle for Life Sciences
Biopharma and medtech companies face a years-long process to get their products approved. Drug and device makers navigate a full spectrum of FDA and global regulatory frameworks to move innovation forward. When the submission process is delayed, it’s rarely due to missing data, but rather conflicting data. i-GENTIC AI ’s newly-evolved GENIE® platform now addresses that challenge by applying contextual reasoning across the full regulatory approval lifecycle.
Bright Uro Receives FDA Clearance for Glean® Abdominal Sensor
Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean® Abdominal Sensor. This new sensor expands the capabilities of the Glean® Urodynamics System to include multi-channel urodynamic studies. This comprehensive system enables wireless, catheter-free ambulatory urodynamics designed to support clinical decision making for patients with LUTD and other urological conditions.
Clinical Studies and Trials
International Research Focuses on Deuterium Depletion – Hungarian Scientific Discovery May Bring a Paradigm Shift in the Treatment of Chronic Diseases
HYD LLC., the organizer of the 5th International Congress on Deuterium Depletion and its satellite event, the Aqua-Synapse research program workshop, announced that researchers from 12 countries demonstrated that recognition of deuterium’s regulatory role in biological systems could fundamentally rewrite current therapeutic approaches. The Aqua-Synapse research program workshop was supported by the European Commission’s Research Executive Agency (REA), in Budapest.
Events
BIO International Convention
When: June 22-25, 2026
Where: San Diego, CA
Event Page
Register for this event.
Touted as the largest and most comprehensive event for biotechnology, the BIO International Convention includes the full ecosystem of biotech. Organizers explain that it is the place to reconnect with your “why”—or the place where you remember your goal is to improve lives. It also fosters building relationships and making connections through their proprietary BIO Partnering meeting-scheduling platform, which is available with the Premier Access registrations.
ADLM Clinical Lab Expo (formerly AACC)
When: July 26-30, 2026
Where: Anaheim, CA
Event Page
Register for this event.
ADLM, which is the leading association for laboratory professionals, holds an annual clinical lab expo to discuss the latest science and prepare for what’s next in the field. Attendees have the opportunity to connect with leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of laboratory medicine. These connections and information sharing is done through lectures, plenary sessions, scientific sessions, and roundtable sessions.
HLTH USA
When: November 15-18, 2026
Where: Las Vegas, NV
Event Page
Register for this event.
HLTH USA brings together professionals from pharma, tech, AI, health systems, and more to showcase healthcare and wellness innovation and how it may transform health. This year’s event will focus on ROI and accelerating goals. The overall goal of the conference is to bring together the healthcare ecosystem while creating “micro-experiences” tailored to participants.
